The addition of a new 300mg presentation allows for greater dosing flexibility to ease overall treatment burden and discomfort. The interchangeable biosimilar was originally approved in March 2025 in ...

A family outing to a mall in New Hampshire turned in an instant when a child picked up a syringe that was laying in the middle of the floor. WBZ-TV's Brandon Truitt reports. Trump Makes Prediction ...

A family outing to a mall in New Hampshire turned in an instant when a child picked up a syringe that was laying in the middle of the floor. WBZ-TV's Brandon Truitt reports. Opinion: Jen Psaki is ...

On October 21, 2025, GSK announced that the European Medicine Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion for the shingle vaccine SHINGRIX ...

Novartis is pulling back the curtain on late-stage Sjögren’s wins, revealing an edge for its investigational monoclonal antibody ianalumab over placebo in both studies. “Clearly, with Sjögren's having ...

ZURICH--(BUSINESS WIRE)--Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® ...

Novartis AG (NYSE:NVS) is one of the 11 Best Annual Dividend Stocks to Buy According to Hedge Funds. The company’s positive outlook strengthens with new updates on ianalumab and Leqvio. Novartis AG ...

Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A doctor or healthcare professional will administer the medication as an injection under the skin. Original ...

Inclisiran (Leqvio) may now be used as a first-line treatment option for patients with high cholesterol levels, according to an announcement from drugmaker Novartis. The US Food and Drug ...

LONG BEACH, Calif. -- Prefilled syringes to treat macular degeneration caused larger and more frequent spikes in intraocular pressure (IOP) as compared with medication drawn from vials, a study of ...

FRANKLIN LAKES, N.J., Aug. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest more than $35 million ...